External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home APVRS 2023
Roche and Genentech at

APVRS 2023

December 08 - December 10
Hong Kong Convention and Exhibition Centre,Hong Kong
apvrs.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
01:24 AM
Duration 6mins S422
Faricimab▼ Treatment Outcomes With Extended Dosing and Potential for Q20W Intervals in DME: A Post Hoc Analysis of the Phase 3 YOSEMITE/RHINE Trials
Hsieh Y, Lim J, Singer M, Idowu O, Hill L, Gibson K
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
01:36 AM
Duration 6mins S422
Efficacy, durability, and safety of faricimab▼ in diabetic macular edema (DME): 1-year results from China subpopulation of phase 3 RHINE trial
Sun, X, Li X, Jiang Q, Idowu O, Tang Y, Liu R
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
01:42 AM
Duration 6mins S422
Efficacy, Durability and Safety of Faricimab▼ in nAMD: 48-Week Results From the China Subpopulation of Phase 3 LUCERNE
Chen Y, Zhang M, Sun D, Li S, Patel S, Liu R
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:30 AM
Duration 6mins S422
Long-Term Efficacy and Safety of the Port Delivery System With Ranibizumab (PDS) in Patients With Neovascular Age-Related Macular Degeneration (nAMD): Results From the Portal 5-Year Subgroup Analysis
Cheung G, Nielsen J, Howard J, Cavichini Cordeiro M, Singh N, Gune S
Ophthalmology | Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:36 AM
Duration 6mins S422
Extended Treatment Outcomes and the Potential for Q20W Dosing With Faricimab▼ in Neovascular Age-Related Macular Degeneration: a Post Hoc Analysis of the Pivotal TENAYA/LUCERNE Trials
Koh A, Singer M, Hill L, Kotecha A, Margaron P
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:54 AM
Duration 6mins S422
Biomarkers for Vascular Stability Demonstrate the Benefit of Dual Ang-2/VEGF-A Inhibition With Faricimab▼ in Phase 3 Trials in DME
Tan C, Maunz A, Patel K, von Schulthess E, Wang T, Willis J
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:06 AM
Duration 6mins S422
Greater Reduction in Pigment Epithelial Detachment Size With Faricimab▼ vs Aflibercept During Head-to-Head Dosing in Patients With Neovascular Age-Related Macular Degeneration
Lai T, Khanani A, Margaron P, Souverain A, Patel S
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:24 AM
Duration 6mins S422
Port Delivery System With Ranibizumab (PDS) in Diabetic Macular Edema (DME): Primary Analysis and Patient Preference Results of the Phase 3 Pagoda Trial
Lai T, Klufas M, Graff J, Campochiaro P, Tian K
Ophthalmology

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
12:48 AM
Duration 8mins 0163 - Symposium
Efficacy and Safety of Faricimab in ALTIMETER: A Trial Exploring Biomarkers of Ang-2 Inhibition in Patients With DME
Vujosevic S
Ophthalmology

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:00 AM
Duration 5mins Hong Kong
Greater Reduction in Macular Leakage in DME With Faricimab▼ vs Aflibercept
Fung N, Sivaprasad S, Goldberg R, Nudleman E, Wang T, Mar F
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.